We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers.
- Authors
Xun Zhang; Mingpeng Luo; Jiahang Zhang; Bize Guo; Singh, Shreya; Xixi Lin; Hanchu Xiong; Siwei Ju; Linbo Wang; Yulu Zhou; Jichun Zhou
- Abstract
Systemic therapy is one of the most significant cancer treatments. However, drug resistance often appears and has become the primary cause of cancer therapy failure. Regulation of drug target, drug metabolism and drug efflux, cell death escape (apoptosis, autophagy, et al.), epigenetic changes, and many other variables are complicatedly involved in the mechanisms of drug resistance. In various types of cancers, long non-coding RNA H19 (lncRNA H19) has been shown to play critical roles in tumor development, proliferation, metastasis, and multiple drug resistance as well. The efficacy of chemotherapy, endocrine therapy, and targeted therapy are all influenced by the expression of H19, especially in breast cancer, liver cancer, lung cancer and colorectal cancer. Here, we summarize the relationship between lncRNA H19 and tumorigenesis, and illustrate the drug resistance mechanisms caused by lncRNA H19 as well. This review may provide more therapeutic potential targets for future cancer treatments.
- Subjects
MULTIDRUG resistance; LINCRNA; DRUG resistance; NEOPLASTIC cell transformation; HORMONE therapy
- Publication
Frontiers in Genetics, 2022, Vol 13, p1
- ISSN
1664-8021
- Publication type
Article
- DOI
10.3389/fgene.2022.1005522